Early Data From Novavax COVID-19 Vaccine Shows Promise

Nova VAX, a biotechnology company, released its phase one data showing that their vaccine, when administered in two doses, led to the development of four times more antibodies in test subjects compared to those with previous COVID-19 antibodies. The vaccine was deemed safe, with no serious side effects, only mild reactions lasting about two days. The findings have been submitted to a medical journal but are yet to be reviewed by external scientists.

What was the key finding about the antibodies in test subjects who received the Nova VAX vaccine?

• They developed no antibodies at all.

• They developed the same amount of antibodies as those with previous COVID-19.

• They developed fewer antibodies than those with previous COVID-19.

• They developed four times more antibodies than those with previous COVID-19.

What did Nova VAX report about the safety of their vaccine?

• It caused mild reactions in some subjects.

• It caused no side effects at all.

• It was not tested for safety.

• It caused severe side effects in all subjects.

How long did the mild side effects last for those who received the Nova VAX vaccine?

• One week

• Two days

• One day

• One month

What is the current status of the findings from Nova VAX's phase one data?

• They have been published in a medical journal.

• They have been peer-reviewed by external scientists.

• They have been submitted to a medical journal but not yet reviewed.

• They have been rejected by a medical journal.

Who reported the news about Nova VAX's phase one data?

• John Doe

• Catherine Beak

• Jane Smith

• Michael Johnson